<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40684156</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2261</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>19</Day></PubDate></JournalIssue><Title>BMC cardiovascular disorders</Title><ISOAbbreviation>BMC Cardiovasc Disord</ISOAbbreviation></Journal><ArticleTitle>Preventive percutaneous coronary intervention versus optimal medical therapy for vulnerable plaque: a meta-analysis.</ArticleTitle><Pagination><StartPage>531</StartPage><MedlinePgn>531</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">531</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12872-025-05005-y</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The effectiveness and safety of preventive percutaneous coronary intervention (PCI) on non-flow limiting vulnerable coronary plaque remain uncertain.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of this meta-analysis was to evaluate the impact of preventive PCI plus optimal medical therapy (OMT) in non-flow limiting vulnerable plaque on clinical outcomes compared with OMT alone.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We searched PubMed, Embase, Web of Science (WOS), and the Cochrane from inception date to October 2024 for relevant studies which compared OMT and PCI plus OMT for non-flow limiting vulnerable plaques. Of the included studies, vulnerable plaques were defined as angiographically intermediate and non-flow limiting plaques with one or more of the following characteristics such as thin-cap fibroatheromas (TCFA), high lipid content, large plaque burden or small luminal area, although specific criteria differed among studies. The primary outcome was major adverse cardiac event (MACE). Pooled risk ratios (RR) were calculated using random effects models and heterogeneity was evaluated with the I<sup>2</sup> statistic.</AbstractText><AbstractText Label="RESULT" NlmCategory="RESULTS">We included 4 randomized clinical trials with 1,843 participants. The follow-up duration ranged from 6 to 25 months. Patients in PCI group had similar incidence of MACE compared with OMT group (RR&#x2009;=&#x2009;0.38; 95% CI 0.10 to 1.45; P&#x2009;=&#x2009;0.16). For individual components of MACE, there were no statistical differences in the incidence of all-cause death, myocardial infarction (RR&#x2009;=&#x2009;0.55; 95% CI 0.05 to 6.51; P&#x2009;=&#x2009;0.64; RR&#x2009;=&#x2009;0.81; 95% CI 0.12 to 5.19; P&#x2009;=&#x2009;0.82). However, compared with OMT group, PCI group experienced a reduction of clinically-driven revascularization and hospitalization for unstable or progressive angina (RR&#x2009;=&#x2009;0.11; 95% CI: 0.03-0.40; P&#x2009;&lt;&#x2009;0.001; RR&#x2009;=&#x2009;0.16; 95% CI: 0.05-0.56; P&#x2009;=&#x2009;0.004).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In patients with non-flow limiting vulnerable plaques, preventive PCI plus OMT showed a similar incidence of MACE but a reduction in the incidence of clinically-driven revascularization and hospitalizations for unstable or progressive angina, compared with OMT alone.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Chen</LastName><ForeName>Yating</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Center for Coronary Artery Disease, Division of Cardiology, Beijing Anzhen Hospital, Capital Medical University, No. 2, Anzhen Road, Chao Yang District, Beijing, 100029, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Liu</LastName><ForeName>Xiaochen</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Center for Coronary Artery Disease, Division of Cardiology, Beijing Anzhen Hospital, Capital Medical University, No. 2, Anzhen Road, Chao Yang District, Beijing, 100029, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Yuyao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Center for Coronary Artery Disease, Division of Cardiology, Beijing Anzhen Hospital, Capital Medical University, No. 2, Anzhen Road, Chao Yang District, Beijing, 100029, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Center for Coronary Artery Disease, Division of Cardiology, Beijing Anzhen Hospital, Capital Medical University, No. 2, Anzhen Road, Chao Yang District, Beijing, 100029, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Feiyu</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Center for Coronary Artery Disease, Division of Cardiology, Beijing Anzhen Hospital, Capital Medical University, No. 2, Anzhen Road, Chao Yang District, Beijing, 100029, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nie</LastName><ForeName>Shaoping</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Coronary Artery Disease, Division of Cardiology, Beijing Anzhen Hospital, Capital Medical University, No. 2, Anzhen Road, Chao Yang District, Beijing, 100029, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Liu</LastName><ForeName>Hongtao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Shenzhen Longhua District Central Hospital, The Affiliated Central Hospital of Shenzhen Longhua District, Guangdong Medical University, Shenzhen, China. lht1376@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Long</LastName><ForeName>Deyong</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center for Coronary Artery Disease, Division of Cardiology, Beijing Anzhen Hospital, Capital Medical University, No. 2, Anzhen Road, Chao Yang District, Beijing, 100029, China. dragon2008@vip.sina.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wang</LastName><ForeName>Xiao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Cardiometabolic Medicine Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167A, Beilishi Road, Xicheng District, Beijing, 100037, China. spaceeye123@126.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>A2022364</GrantID><Agency>2020 Guangdong Provincial Medical Research Fund</Agency><Country/></Grant><Grant><GrantID>2022YFC2505600</GrantID><Agency>National Key R&amp;D Program of China</Agency><Country/></Grant><Grant><GrantID>JQ24039</GrantID><Agency>Beijing Municipal Natural Science Foundation Grant</Agency><Country/></Grant><Grant><GrantID>82470339</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>2024-I2M-3-020</GrantID><Agency>CAMS Innovation Fund for Medical Sciences</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Cardiovasc Disord</MedlineTA><NlmUniqueID>100968539</NlmUniqueID><ISSNLinking>1471-2261</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002317">Cardiovascular Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002317" MajorTopicYN="Y">Cardiovascular Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003324" MajorTopicYN="Y">Coronary Artery Disease</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="Y">Percutaneous Coronary Intervention</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058226" MajorTopicYN="Y">Plaque, Atherosclerotic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Optimal medical therapy</Keyword><Keyword MajorTopicYN="N">Percutaneous coronary intervention</Keyword><Keyword MajorTopicYN="N">Vulnerable plaque</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: Ethical approval and consent to participate were not applicable for this meta-analysis. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>20</Day><Hour>4</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>20</Day><Hour>4</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>19</Day><Hour>23</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40684156</ArticleId><ArticleId IdType="pmc">PMC12275282</ArticleId><ArticleId IdType="doi">10.1186/s12872-025-05005-y</ArticleId><ArticleId IdType="pii">10.1186/s12872-025-05005-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation. 1989;79(4):733&#x2013;43. 10.1161/01.cir.79.4.733.</Citation><ArticleIdList><ArticleId IdType="pubmed">2647318</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaba P, Gersh BJ, Muller J, et al. Evolving concepts of the vulnerable atherosclerotic plaque and the vulnerable patient: implications for patient care and future research. Nat Rev Cardiol. 2023;20(3):181&#x2013;96. 10.1038/s41569-022-00769-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">36151312</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedhi E, Berta B, Roleder T, et al. Thin-cap fibroatheroma predicts clinical events in diabetic&#x2002;patients with normal fractional flow reserve: the COMBINE OCT-FFR trial. Eur Heart J. 2021;42(45):4671&#x2013;9. 10.1093/eurheartj/ehab433.</Citation><ArticleIdList><ArticleId IdType="pubmed">34345911</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol JQ, Volleberg R, Belkacemi A, et al. Fractional flow reserve-negative high-risk plaques and clinical outcomes after myocardial infarction. JAMA Cardiol. 2023;8(11):1013&#x2013;21. 10.1001/jamacardio.2023.2910.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10500430</ArticleId><ArticleId IdType="pubmed">37703036</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H, Ahn JM, Kang DY, et al. Management of coronary vulnerable plaque with medical therapy or local preventive percutaneous coronary intervention. JACC Asia. 2024;4(6):425&#x2013;43. 10.1016/j.jacasi.2024.04.001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11291350</ArticleId><ArticleId IdType="pubmed">39100699</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomaniak M, Katagiri Y, Modolo R, et al. Vulnerable plaques and patients: state-of-the-art. Eur Heart J. 2020;41(31):2997&#x2013;3004. 10.1093/eurheartj/ehaa227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8453282</ArticleId><ArticleId IdType="pubmed">32402086</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallone G, Bellettini M, Gatti M, et al. Coronary plaque characteristics associated with major adverse cardiovascular events in atherosclerotic patients and lesions: a systematic review and meta-analysis. JACC Cardiovasc Imaging. 2023;16(12):1584&#x2013;604. 10.1016/j.jcmg.2023.08.006.</Citation><ArticleIdList><ArticleId IdType="pubmed">37804276</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87&#x2013;165. 10.1093/eurheartj/ehy394.</Citation><ArticleIdList><ArticleId IdType="pubmed">30165437</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2022;145(3):e4-17. 10.1161/cir.0000000000001039.</Citation><ArticleIdList><ArticleId IdType="pubmed">34882436</ArticleId></ArticleIdList></Reference><Reference><Citation>Wykrzykowska JJ, Kraak RP, Hofma SH, et al. Bioresorbable scaffolds versus metallic stents in routine PCI. N Engl J Med. 2017;376(24):2319&#x2013;28. 10.1056/NEJMoa1614954.</Citation><ArticleIdList><ArticleId IdType="pubmed">28402237</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Lara J, Brugaletta S, Farooq V, et al. Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography. JACC Cardiovasc Interv. 2011;4(12):1271&#x2013;80. 10.1016/j.jcin.2011.08.016.</Citation><ArticleIdList><ArticleId IdType="pubmed">22192368</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourantas CV, Papafaklis MI, Kotsia A, et al. Effect of the endothelial shear stress patterns on neointimal proliferation following drug-eluting bioresorbable vascular scaffold implantation: an optical coherence tomography study. JACC Cardiovasc Interv. 2014;7(3):315&#x2013;24. 10.1016/j.jcin.2013.05.034.</Citation><ArticleIdList><ArticleId IdType="pubmed">24529931</ArticleId></ArticleIdList></Reference><Reference><Citation>Wykrzykowska JJ, Diletti R, Gutierrez-Chico JL, et al. Plaque sealing and passivation with a mechanical self-expanding low outward force nitinol vShield device for the treatment of IVUS and OCT-derived thin cap fibroatheromas (TCFAs) in native coronary arteries: report of the pilot study vShield evaluated at cardiac hospital in Rotterdam for investigation and treatment of TCFA (SECRITT). EuroIntervention. 2012;8(8):945&#x2013;54. 10.4244/eijv8i8a144.</Citation><ArticleIdList><ArticleId IdType="pubmed">22669133</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone GW, Maehara A, Ali ZA, et al. Percutaneous coronary intervention for vulnerable coronary atherosclerotic plaque. J Am Coll Cardiol. 2020;76(20):2289&#x2013;301. 10.1016/j.jacc.2020.09.547.</Citation><ArticleIdList><ArticleId IdType="pubmed">33069847</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SJ, Ahn JM, Kang DY, et al. Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial. Lancet. 2024;403(10438):1753&#x2013;65. 10.1016/s0140-6736(24)00413-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">38604213</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol JQ, Bom MJ, Damman P, et al. Pre-Emptive OCT-Guided angioplasty of vulnerable intermediate coronary lesions: results from the prematurely halted PECTUS-trial. J Interv Cardiol. 2020;2020:8821525. 10.1155/2020/8821525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7737444</ArticleId><ArticleId IdType="pubmed">33363447</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. 10.1136/bmj.n71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Erlinge D, Maehara A, Ben-Yehuda O, et al. Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study. Lancet. 2021;397(10278):985&#x2013;95. 10.1016/s0140-6736(21)00249-x.</Citation><ArticleIdList><ArticleId IdType="pubmed">33714389</ArticleId></ArticleIdList></Reference><Reference><Citation>Waksman R, Di Mario C, Torguson R, et al. Identification of patients and plaques vulnerable to future coronary events with near-infrared spectroscopy intravascular ultrasound imaging: a prospective, cohort study. Lancet. 2019;394(10209):1629&#x2013;37. 10.1016/s0140-6736(19)31794-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">31570255</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng JM, Garcia-Garcia HM, de Boer SP, et al. In vivo detection of high-risk coronary plaques by radiofrequency intravascular ultrasound and cardiovascular outcome: results of the ATHEROREMO-IVUS study. Eur Heart J. 2014;35(10):639&#x2013;47. 10.1093/eurheartj/eht484.</Citation><ArticleIdList><ArticleId IdType="pubmed">24255128</ArticleId></ArticleIdList></Reference><Reference><Citation>Prati F, Romagnoli E, Gatto L, et al. Relationship between coronary plaque morphology of the left anterior descending artery and 12 months clinical outcome: the CLIMA study. Eur Heart J. 2020;41(3):383&#x2013;91. 10.1093/eurheartj/ehz520.</Citation><ArticleIdList><ArticleId IdType="pubmed">31504405</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubo T, Ino Y, Mintz GS, et al. Optical coherence tomography detection of vulnerable plaques at high risk of developing acute coronary syndrome. Eur Heart J Cardiovasc Imaging. 2021. 10.1093/ehjci/jeab028.</Citation><ArticleIdList><ArticleId IdType="pubmed">33619524</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang S, Fang C, Xu X, et al. Identification of high-risk coronary lesions by 3-vessel optical coherence tomography. J Am Coll Cardiol. 2023;81(13):1217&#x2013;30. 10.1016/j.jacc.2023.01.030.</Citation><ArticleIdList><ArticleId IdType="pubmed">36925409</ArticleId></ArticleIdList></Reference><Reference><Citation>Nurmohamed NS, van Rosendael AR, Danad I, et al. Atherosclerosis evaluation and cardiovascular risk estimation using coronary computed tomography angiography. Eur Heart J. 2024;45(20):1783&#x2013;800. 10.1093/eurheartj/ehae190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11129796</ArticleId><ArticleId IdType="pubmed">38606889</ArticleId></ArticleIdList></Reference><Reference><Citation>Puchner SB, Liu T, Mayrhofer T, et al. High-risk plaque detected on coronary CT angiography predicts acute coronary syndromes independent of significant stenosis in acute chest pain: results from the ROMICAT-II trial. J Am Coll Cardiol. 2014;64(7):684&#x2013;92. 10.1016/j.jacc.2014.05.039.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4135448</ArticleId><ArticleId IdType="pubmed">25125300</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams MC, Kwiecinski J, Doris M, et al. Low-Attenuation noncalcified plaque on coronary computed tomography angiography predicts myocardial infarction: results from the multicenter SCOT-HEART trial (Scottish computed tomography of the HEART). Circulation. 2020;141(18):1452&#x2013;62. 10.1161/circulationaha.119.044720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7195857</ArticleId><ArticleId IdType="pubmed">32174130</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai R, Chang C, Zhong X, et al. Lowering of blood lipid levels with a combination of Pitavastatin and ezetimibe in patients with coronary heart disease: a meta-analysis. CVIA. 2023;7(1). 10.15212/cvia.2023.0004.</Citation></Reference><Reference><Citation>R&#xe4;ber L, Ueki Y, Otsuka T, et al. Effect of Alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial. JAMA. 2022;327(18):1771&#x2013;81. 10.1001/jama.2022.5218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8978048</ArticleId><ArticleId IdType="pubmed">35368058</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourantas CV, Serruys PW, Nakatani S, et al. Bioresorbable vascular scaffold treatment induces the formation of neointimal cap that seals the underlying plaque without compromising the luminal dimensions: a concept based on serial optical coherence tomography data. EuroIntervention. 2015;11(7):746&#x2013;56. 10.4244/eijy14m10_06.</Citation><ArticleIdList><ArticleId IdType="pubmed">25308301</ArticleId></ArticleIdList></Reference><Reference><Citation>Akpek M, Sahin O, Sarli B, et al. Acute effects of intracoronary Tirofiban on no-reflow phenomena in patients with ST-segment elevated myocardial infarction undergoing primary percutaneous coronary intervention. Angiology. 2015;66(6):560&#x2013;7. 10.1177/0003319714545780.</Citation><ArticleIdList><ArticleId IdType="pubmed">25092681</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet Inhibition with Cangrelor during PCI on ischemic events. N Engl J Med. 2013;368(14):1303&#x2013;13. 10.1056/NEJMoa1300815.</Citation><ArticleIdList><ArticleId IdType="pubmed">23473369</ArticleId></ArticleIdList></Reference><Reference><Citation>Gargiulo G, Cirillo P, Sperandeo L, et al. Pharmacodynamic effects of Cangrelor in patients with acute or chronic coronary syndrome undergoing percutaneous coronary intervention: the POMPEII registry. EuroIntervention. 2025;21(10):560&#x2013;70. 10.4244/eij-d-24-00757.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC12063553</ArticleId><ArticleId IdType="pubmed">40375762</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720&#x2013;826. 10.1093/eurheartj/ehad191.</Citation><ArticleIdList><ArticleId IdType="pubmed">37622654</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia H, Dai J, Hou J, et al. Effective anti-thrombotic therapy without stenting: intravascular optical coherence tomography-based management in plaque erosion (the EROSION study). Eur Heart J. 2017;38(11):792&#x2013;800. 10.1093/eurheartj/ehw381.</Citation><ArticleIdList><ArticleId IdType="pubmed">27578806</ArticleId></ArticleIdList></Reference><Reference><Citation>Castiello DS, Buongiorno F, Manzi L, et al. Procedural and antithrombotic therapy optimization in patients with atrial fibrillation undergoing percutaneous coronary intervention: a narrative review. J Cardiovasc Dev Dis. 2025;12(4). 10.3390/jcdd12040142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC12028227</ArticleId><ArticleId IdType="pubmed">40278201</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim MC, Park SJ, Park DW, et al. Preventive percutaneous coronary intervention for non-flow-limiting vulnerable atherosclerotic coronary plaques in diabetes: the PREVENT trial. Eur Heart J. 2025. 10.1093/eurheartj/ehaf273.</Citation><ArticleIdList><ArticleId IdType="pubmed">40439104</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbab-Zadeh A, Fuster V. From detecting the vulnerable plaque to managing the vulnerable patient: JACC State-of-the-Art review. J Am Coll Cardiol. 2019;74(12):1582&#x2013;93. 10.1016/j.jacc.2019.07.062.</Citation><ArticleIdList><ArticleId IdType="pubmed">31537269</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>